PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).

Abstract What's known on the subject? and What does the study add? The interest in metastatic renal cell carcinoma has increased in the last few years, mainly due to the advent of targeted therapies, but metastasectomy remains the sole therapy that can lead to a complete and durable regression, even if only in a minority of patients. The literature reports quite large series of metastasectomies for the most common sites of metastasis, e.g. lung, liver, bone, adrenal and brain, whereas little is known about the management of metastasis in 'atypical' sites. The prognosis of patients submitted to metastasectomy for a metastasis in an atypical site is equivalent to patients with lung metastasis. The characteristics of the primary tumour in these patients are not indicative, but atypical metastasis (AM) are often located in superficial sites and frequently associated with other metastases. So, physical examination should be included in all follow-up regimens and a complete re-staging should be performed after the diagnosis of an AM.
PMID
Related Publications

Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.

Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.

Prognostic role of tumour multifocality in renal cell carcinoma.

The influence of the primary tumor on the long-term results of pulmonary metastasectomy for metastatic renal cell carcinoma.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Authors

Mayor MeshTerms

Nephrectomy

Keywords
Journal Title bju international
Publication Year Start




PMID- 22639956
OWN - NLM
STAT- MEDLINE
DCOM- 20130423
LR  - 20130307
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 110
IP  - 11 Pt B
DP  - 2012 Dec
TI  - Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
PG  - E559-63
LID - 10.1111/j.1464-410X.2012.11271.x [doi]
AB  - UNLABELLED: What's known on the subject? and What does the study add? The
      interest in metastatic renal cell carcinoma has increased in the last few years, 
      mainly due to the advent of targeted therapies, but metastasectomy remains the
      sole therapy that can lead to a complete and durable regression, even if only in 
      a minority of patients. The literature reports quite large series of
      metastasectomies for the most common sites of metastasis, e.g. lung, liver, bone,
      adrenal and brain, whereas little is known about the management of metastasis in 
      'atypical' sites. The prognosis of patients submitted to metastasectomy for a
      metastasis in an atypical site is equivalent to patients with lung metastasis.
      The characteristics of the primary tumour in these patients are not indicative,
      but atypical metastasis (AM) are often located in superficial sites and
      frequently associated with other metastases. So, physical examination should be
      included in all follow-up regimens and a complete re-staging should be performed 
      after the diagnosis of an AM. OBJECTIVE: * To review the clinical characteristics
      and oncological results in patients submitted to surgical removal of metastasis
      from renal cell carcinoma (RCC) in atypical sites (atypical metastasis [AM], i.e.
      metastasis in sites other than the chest, liver, bone, adrenal, brain, kidney,
      and lymph nodes), compared with patients submitted to metastasectomy due to a
      lung metastasis (LM). PATIENTS AND METHODS: * From an institutional database of
      approximately 1800 patients surgically treated for a RCC, we retrospectively
      identified 37 cases that had undergone metastasectomy for AM and 57 operated for 
      LM. * Clinicopathological features of the primary RCC and metastasis, and
      cancer-specific survival (CSS) computed from the time of metastasectomy of
      patients with AM and LM, were compared. * A univariate and multivariable analysis
      applying a Cox regression model was used to evaluate CSS. RESULTS: * The patients
      with AM and LM were followed for an average of 40.8 and 50.7 months from
      metastasectomy, respectively (P= 0.372). * There were no significant differences 
      in the characteristics of the primary tumour between patients with AM and LM. *
      In the cases with AM and LM the diagnosis was simultaneous with that of the
      primary tumour in 32.4% and 24.6%, (P= 0.40) respectively, and, when
      metachronous, occurred at an average delay of 53.4 and 44.3 months (P= 0.370). * 
      More frequently in the cases with AM other metastases had been diagnosed in the
      previous medical history (35.2 vs 8.8%, P= 0.001) or simultaneously (48.6 vs
      8.8%, P= 0.001). * CSS from metastasectomy was affected by the synchronicity in
      diagnosis between metastasis and primary tumour, and by the simultaneous presence
      of other metastases, while the type of metastasis (AM vs LM) did not affect CSS. 
      In fact, metastasectomy in AM was as effective as in LM. CONCLUSION: * AM are an 
      exceptional presentation of metastatic RCC, but the role of surgery is similar to
      that of pulmonary metastasis. In these cases, metastasectomy is accepted as
      possible care, and in AM the CSS after metastasectomy is similar.
CI  - (c) 2012 THE AUTHORS. BJU INTERNATIONAL (c) 2012 BJU INTERNATIONAL.
FAU - Antonelli, Alessandro
AU  - Antonelli A
AD  - Division of Urology, University of Brescia and Spedali Civili di Brescia
      Hospital, Brescia, Italy.
FAU - Arrighi, Nicola
AU  - Arrighi N
FAU - Corti, Serena
AU  - Corti S
FAU - Legramanti, Stefano
AU  - Legramanti S
FAU - Zanotelli, Tiziano
AU  - Zanotelli T
FAU - Cozzoli, Alberto
AU  - Cozzoli A
FAU - Cunico, Sergio Cosciani
AU  - Cunico SC
FAU - Simeone, Claudio
AU  - Simeone C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120528
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
SB  - IM
MH  - Aged
MH  - Carcinoma, Renal Cell/mortality/*secondary/surgery
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Italy/epidemiology
MH  - Kidney Neoplasms/mortality/*pathology/surgery
MH  - Lung Neoplasms/mortality/*secondary/surgery
MH  - Male
MH  - Metastasectomy/*methods
MH  - Middle Aged
MH  - *Nephrectomy
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - Survival Rate/trends
MH  - Treatment Outcome
EDAT- 2012/05/30 06:00
MHDA- 2013/04/24 06:00
CRDT- 2012/05/30 06:00
PHST- 2012/05/30 06:00 [entrez]
PHST- 2012/05/30 06:00 [pubmed]
PHST- 2013/04/24 06:00 [medline]
AID - 10.1111/j.1464-410X.2012.11271.x [doi]
PST - ppublish
SO  - BJU Int. 2012 Dec;110(11 Pt B):E559-63. doi: 10.1111/j.1464-410X.2012.11271.x.
      Epub 2012 May 28.